Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Zealand Pharma A/S
  6. Summary
    ZEAL   DK0060257814

ZEALAND PHARMA A/S

(ZEAL)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-10-03 am EDT
167.50 DKK   -3.62%
09/30Transcript : Zealand Pharma A/S - Special Call
CI
09/30Zealand Pharma Says Potential Treatment for Short Bowel Syndrome Met Primary Endpoint in Phase 3 Trial
MT
09/30Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
09/27/2022 09/28/2022 09/29/2022 09/30/2022 10/03/2022 Date
129.2(c) 132.1(c) 135.3(c) 173.8(c) 167.5(c) Last
97 523 72 701 202 858 1 384 043 592 103 Volume
-0.39% +2.24% +2.42% +28.46% -3.62% Change
More quotes
Estimated financial data (e)
Sales 2022 136 M 18,0 M 18,0 M
Net income 2022 -1 001 M -132 M -132 M
Net cash position 2022 55,3 M 7,31 M 7,31 M
P/E ratio 2022 -6,68x
Yield 2022 -
Sales 2023 862 M 114 M 114 M
Net income 2023 -497 M -65,7 M -65,7 M
Net cash position 2023 986 M 130 M 130 M
P/E ratio 2023 -21,9x
Yield 2023 -
Capitalization 7 752 M 1 025 M 1 025 M
EV / Sales 2022 56,4x
EV / Sales 2023 7,85x
Nbr of Employees 237
Free-Float 99,0%
More Financials
Company
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product... 
Sector
Biotechnology & Medical Research
Calendar
11/10 | 09:00amEarnings Release
More about the company
Ratings of Zealand Pharma A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ZEALAND PHARMA A/S
09/30Transcript : Zealand Pharma A/S - Special Call
CI
09/30Zealand Pharma Says Potential Treatment for Short Bowel Syndrome Met Primary Endpoint i..
MT
09/30Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patient..
GL
09/30Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patient..
AQ
09/30Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Pat..
CI
09/29Zealand Pharma A/S(NasdaqGS:ZEAL) dropped from NASDAQ Compos..
CI
09/22European ADRs Move Lower in Thursday Trading
MT
09/21Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th An..
GL
09/21Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th An..
AQ
09/20European ADRs Move Lower in Tuesday Trading
MT
09/19European ADRs Move Lower in Monday Trading
MT
09/19Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsu..
GL
09/19Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsu..
GL
09/19Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsu..
CI
09/16European ADRs Move Lower in Friday Trading
MT
More news
News in other languages on ZEALAND PHARMA A/S
09/30Zeland Pharma : le titre flambe après une étude de phase 3
09/22Les ADR européens sont en baisse jeudi
09/20Les ADR européens sont en baisse dans les échanges de mardi
09/19Les ADR européens sont en baisse lundi
09/19Zealand Pharma présente les données de l'essai de phase 3 du Dasiglucagon dans l'hyperi..
More news
Analyst Recommendations on ZEALAND PHARMA A/S
More recommendations
ETFs positioned on ZEALAND PHARMA A/SETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares MSCI Europe Small-Cap ETF - USD0.05%-1.26%Europe
IShares MSCI EAFE Small-Cap ETF - USD0.02%-2.05%EAFE
Vanguard MSCI International Small Companies...0.01%-0.08%-World
Vanguard FTSE Europe ETF - USD0.01%-0.77%Europe
Vanguard FTSE Developed Europe All Cap Inde...0.01%0.24%Europe
More ETFs positioned on ZEALAND PHARMA A/S
Chart ZEALAND PHARMA A/S
Duration : Period :
Zealand Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZEALAND PHARMA A/S
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 167,50 DKK
Average target price 213,33 DKK
Spread / Average Target 27,4%
EPS Revisions
Managers and Directors
Adam Sinding Steensberg President & Chief Executive Officer
Alf Gunnar Martin Nicklasson Chairman
Ivan M. M°ller Executive VP-Technical Development & Operations
Danilo Verge Head-Global Medical Affairs
David M. Kendall Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ZEALAND PHARMA A/S19.78%1 060
GILEAD SCIENCES, INC.-15.04%77 320
VERTEX PHARMACEUTICALS31.85%74 255
REGENERON PHARMACEUTICALS, INC.9.08%73 646
BIONTECH SE-47.68%32 778
WUXI APPTEC CO., LTD.-39.54%29 044